{
    "nctId": "NCT06515470",
    "briefTitle": "Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer",
    "officialTitle": "A First-in-Human, Open-Label, Dose Escalation and Expansion Trial of BTX-9341 in Participants With Advanced and/or Metastatic Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 82,
    "primaryOutcomeMeasure": "Safety and Tolerability of BTX-9341",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic and/or locally advanced HR+/HER2- breast cancer (dose escalation: measurable disease and/or at least 1 lytic or mixed \\[lytic + sclerotic\\] bone lesion that can be assessed by CT or MRI or non-measurable disease \\[including bone lesions\\]; dose expansion: measurable disease)\n* Dose escalation: (a) received not more than 1 chemotherapy in the metastatic/advanced setting; (b) no limit to the lines of endocrine therapy (monotherapy or combination therapy) in the metastatic setting; (c) received CDK4/6 inhibitor therapy\n* Dose expansion: (a) received not more than 1 chemotherapy in metastatic/advanced setting; (b) received not more than 2 lines of endocrine therapy (monotherapy or combination therapy) and must have been on prior endocrine therapy for at least 6 months before progression; (c) received at most 2 lines of CDK4/6 inhibitor therapy (1 in the adjuvant setting and 1 in the metastatic setting) and must have been on prior CDK4/6 inhibitor therapy for at least 6 months\n* Acceptable hematologic function\n\n  1. ANC \u2265 1500 per mL. Note: Use of growth-factors to maintain the ANC criterion is prohibited.\n  2. Platelet count \u2265 100,000 per mL. Note: Use of transfusions or thrombopoietic agents to achieve the baseline platelet count criterion is prohibited.\n  3. Hemoglobin \u2265 9.0 g/dL. Note: Packed red blood cell transfusion is allowed up to 14 days prior to trial entry.\n* Acceptable liver function\n\n  1. Bilirubin \u2264 2.0 \u00d7 institutional upper limit of normal (ULN) (or \\< 3.0 \u00d7 institutional ULN if Gilbert's disease is present)\n  2. Alanine transaminase (ALT)/aspartate aminotransferase (AST) \u2264 3.0 \u00d7 institutional ULN (\u2264 5.0 \u00d7 institutional ULN if liver metastases present)\n  3. Alkaline phosphatase \u2264 2.5 \u00d7 institutional ULN (\u2264 5.0 \u00d7 institutional ULN if bone or liver metastases present)\n* Able and willing to sign informed consent\n* Meets all study requirements in the opinion of the Investigator\n\nExclusion Criteria:\n\n* RB1 (retinoblastoma) gene mutation\n* Symptomatic visceral disease\n* Clinical evidence or history of central nervous system metastasis\n* Abnormalities in coagulation, such as bleeding diathesis, or treatment with anticoagulants precluding injections of fulvestrant or luteinizing hormone-releasing hormone (LHRH) agonist",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}